相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. Garcia-Beltran et al.
CELL (2022)
Winter of Omicron-The Evolving COVID-19 Pandemic
Carlos del Rio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
Wanwisa Dejnirattisai et al.
LANCET (2022)
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Juan Manuel Carreno et al.
NATURE (2022)
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Raquel Viana et al.
NATURE (2022)
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Nick Andrews et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert et al.
SCIENCE (2022)
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Alicia T. Widge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
Aurelien Sokal et al.
CELL (2021)
HOW SEVERE ARE OMICRON INFECTIONS?
Heidi Ledford
NATURE (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Rishi R. Goel et al.
SCIENCE (2021)
Covid-19: Early studies give hope omicron is milder than other variants
Bryan Christie
BMJ-BRITISH MEDICAL JOURNAL (2021)
Antibody evasion by the P.1 strain of SARS-CoV-2
Wanwisa Dejnirattisai et al.
CELL (2021)
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Venkata Viswanadh Edara et al.
CELL HOST & MICROBE (2021)
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Xiaoying Shen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
V. Shinde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu et al.
LANCET (2021)
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Alberto M. Borobia et al.
LANCET (2021)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Amy Flaxman et al.
LANCET (2021)
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
Nassim Kamar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
Johan Normark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Yinon M. Bar-On et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni et al.
CELL (2020)
Validation of a commercially available SARS-CoV-2 serological immunoassay
B. Meyer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns
Nicole Baumgarth et al.
JOURNAL OF IMMUNOLOGY (2020)
SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition
Arne Sattler et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)